期刊文献+

左西孟旦在缺血性心肌病顽固性心力衰竭患者经皮冠状动脉介入治疗中的应用研究 被引量:8

Percutaneous coronary intervention of Levosimendan in ischemic cardiomyopathy patients with refractory heart failure
下载PDF
导出
摘要 目的探讨左西孟旦在缺血性心肌病顽固性心力衰竭患者经皮冠状动脉介入治疗中的作用。方法选择我院行介入治疗的80例冠心病慢性心力衰竭患者随机分为治疗组(40例)和对照组(40例)。对照组给予常规药物治疗,治疗组患者在术前2天给予左西孟旦注射液。所有患者均行冠脉造影检查以确定冠脉病变程度、狭窄程度,并行介入治疗。观察术后肌酐水平,随访术后1月心功能改善情况,包括6分钟步行试验、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)等。结果治疗组共完成完全血运重建38例,对照组共完成完全血运重建25例,差异有统计学意义(P<0.05)。术后1月两组患者临床症状均明显减轻;与术前比较,治疗组心功能改善更加明显(P<0.05)。治疗组术后肌酐水平较对照组降低(P<0.05)。结论在对缺血性心肌病顽固性心力衰竭患者,在介入治疗前应用左西孟旦,可增加患者耐受力,从而增加患者完全血运成功率,降低术后并发症的风险,明显改善术后患者心功能及肾功能水平,以最大程度挽救缺血心肌。 Objective To study the effects of levosimendan in ischemic cardiomyopathy patients with refractory heart failure of per -cutaneous coronary intervention .Methods Eighty cases of coronary intervention in patients with chronic heart failure were randomly divided into treatment group (40 cases) and control group (40 cases).The control group received conventional therapy while treatment group patients were given levosimendan injection two days before surgery .All patients underwent coronary angiography to determine the extent of coronary artery disease and the degree of stenosis ,and received intervention .Postoperative creatinine levels were observed , and heart function situation was followed up,including the 6-minute walk test,left ventricular end-diastolic diameter (LVEDD),left ventric-ular ejection fraction (LVEF), etc.Results Treatment group completed a total of 38 cases of complete revascularization,while the control group completed a total of 25cases of complete revascularization with the difference statistically significant (P〈0.05).Clinical symptoms significantly reduced in the control and treatment group .Treatment group improved heart function more obviously than that before the operation ( P〈0.05 ) .Creatinine level after the operation in treatment group was lower than that in control group ( P〈0.05).Conclusion Ischemic cardiomyopathy refractory heart failure patients injected levosimendan before the intervention increased their tolerance ,increased the success rate of complete blood flow ,reduced the risk of postoperative complications ,improved significantly postoperative cardiac function and renal function levels to save ischemic myocardium to an extreme degree .
出处 《滨州医学院学报》 2013年第6期424-425,428,共3页 Journal of Binzhou Medical University
关键词 左西孟旦 缺血性心肌病 顽固性心力衰竭 介入治疗 levosimendan Ischemic cardiomyopathy Refractory heart failure Intervention
  • 相关文献

参考文献7

  • 1Antoniades C, Tousoulis D, Koumallos N, et al. Levosimendan: be- yond its simple inotropic effect in heart failure[ J]. Pharmacol Ther, 2007,114 (2) :184-197.
  • 2Pathak A, Lebrin M, Vaccaro A,et al. Pharmacology of levosimen- dan: inotropie, vasodilatot and eardioprotective effects [ J ]. J Clin Pharm Ther,2013,38 ( 5 ) :341-349.
  • 3高润霖,刘冰.经皮冠状动脉介入治疗指南[J].中华心血管病杂志,2002,30(12):707-718. 被引量:336
  • 4Chung CM, Nakamura S, Tanaka K, et al. Effect of recanalization of chronic total occlusions on global and regional left ventricular func-tion in patients with or without previous myocardial infarction [ J ]. Catheter Cardiovasc Interv ,2003,60 ( 3 ) :368-374.
  • 5Dagianti A, Rosanio S, Penco M, et al. Clinical and prognostic useful- ness of supine bicycle exercise echocardiography in the functional e- valuation of patients undergoing elective percutaneous transluminal coronary angioplasty [ J ]. Circulation, 1997,95 (5) : 1176-1184.
  • 6Ikonomidis I, Parissis JT, Paraskevaidis I, et al. Effects of levosimen- dan on coronary arteH- flow and cardiac performance in patients with advanced heart failure [J]. Eur J Heart Fail,2007,9 (12) : 1172- 1177.
  • 7Franco F, Goncalves F, Castro G, et al. Levosimendan is efficacious in acute heart failure independent of renal function [ J ]. Eur Heart J,2003,24( suppl 1 ) :408.

共引文献335

同被引文献57

  • 1Canaud B,Bowry S,Tetta C.et al.The case for treating refractory congestive heart failure with ultrafiltration[J].Blood Purif,2014;37(2):51-60.
  • 2Rognoni A,Lupi A,Iazm M,et al.Levosimendan:from besic science to clinical trials[J].Recent Pat Cardiovase Drug Diseov.2011,6(1):5-9.
  • 3Adamo M,Barbanti M,Curello S,et al.Effectiveness of MitraClip therapy in patients with refractory heart failure[J].J Interv Cardio1.2015,28(1):61-68.
  • 4Sevimli S,Aksakal E,Tanboga H,et al.Percutaneous valve-in-valve transcatheter tricuspid valve replacement with simultaneous paravalvular leak closure in a patient with refractory right heart failure[J].JACC Cardiovasc Interv.2014,7(7):79-80.
  • 5Muser D,Nucifora G,Gianfagna E,et al.Clinical spectrum of isolated left ventricular noncompaction:thromboembolic events,malignant left ventricular arrhythmias,and refractory heart failure[J].J Am Colt Cardio1.2014,63(16):39.
  • 6Kurita N,Mise N,Tanaka S,et al.Arteriovenous access closure in hemodialysis patients with refractory heart failure:a single center experience[J].Ther Apher Dia1.2011,15(2):195-202.
  • 7Radlberger P,Adlbrecht C,Mittermayr T.Cardiac contractility modulation inpatients with heart failure refractory to drug treatment[J].Exp Clin Cardio1,2011,16(2)43-46.
  • 8李旭炯,秦富军,张武宁.左西孟坦治疗冠心病伴急性心力衰竭的疗效[J].心血管康复医学杂志,2009,18(5):463-465. 被引量:4
  • 9高峰,李飞,李晓莉.心脏再同步化治疗慢性心力衰竭疗效观察[J].陕西医学杂志,2010,39(4):478-479. 被引量:5
  • 10李真,王莹琦,杨东辉,张树龙,高连君,杨延宗.心脏再同步化治疗顽固性心力衰竭合并心房颤动[J].中华老年多器官疾病杂志,2010,9(2):151-154. 被引量:5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部